Cargando…
ACTH Receptor (MC2R) Specificity: What Do We Know About Underlying Molecular Mechanisms?
Coincidentally, the release of this Research Topic in Frontiers in Endocrinology takes place 25 years after the discovery of the adrenocorticotropic hormone receptor (ACTHR) by Mountjoy and colleagues. In subsequent years, following the discovery of other types of mammalian melanocortin receptors (M...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292628/ https://www.ncbi.nlm.nih.gov/pubmed/28220105 http://dx.doi.org/10.3389/fendo.2017.00013 |
_version_ | 1782504959311347712 |
---|---|
author | Fridmanis, Davids Roga, Ance Klovins, Janis |
author_facet | Fridmanis, Davids Roga, Ance Klovins, Janis |
author_sort | Fridmanis, Davids |
collection | PubMed |
description | Coincidentally, the release of this Research Topic in Frontiers in Endocrinology takes place 25 years after the discovery of the adrenocorticotropic hormone receptor (ACTHR) by Mountjoy and colleagues. In subsequent years, following the discovery of other types of mammalian melanocortin receptors (MCRs), ACTHR also became known as melanocortin type 2 receptor (MC2R). At present, five types of MCRs have been reported, all of which share significant sequence similarity at the amino acid level, and all of which specifically bind melanocortins (MCs)—a group of biologically active peptides generated by proteolysis of the proopiomelanocortin precursor. All MCs share an identical –H–F–R–W– pharmacophore sequence. α-Melanocyte-stimulating hormone (α-MSH) and adrenocorticotropic hormone (ACTH) are the most extensively studied MCs and are derived from the same region. Essentially, α-MSH is formed from the first 13 amino acid residues of ACTH. ACTHR is unique among MCRs because it binds one sole ligand—ACTH, which makes it a very attractive research object for molecular pharmacologists. However, much research has failed, and functional studies of this receptor are lagging behind other MCRs. The reason for these difficulties has already been outlined by Mountjoy and colleagues in their publication on ACTHR coding sequence discovery where the Cloudman S91 melanoma cell line was used for receptor expression because it was a “more sensitive assay system.” Subsequent work showed that ACTHR could be successfully expressed only in endogenous MCR-expressing cell lines, since in other cell lines it is retained within the endoplasmic reticulum. The resolution of this methodological problem came in 2005 with the discovery of melanocortin receptor accessory protein, which is required for the formation of functionally active ACTHR. The decade that followed this discovery was filled with exciting research that provided insight into the molecular mechanisms underlying the action of ACTHR. The purpose of this review is to summarize the advances in this fascinating research field. |
format | Online Article Text |
id | pubmed-5292628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-52926282017-02-20 ACTH Receptor (MC2R) Specificity: What Do We Know About Underlying Molecular Mechanisms? Fridmanis, Davids Roga, Ance Klovins, Janis Front Endocrinol (Lausanne) Endocrinology Coincidentally, the release of this Research Topic in Frontiers in Endocrinology takes place 25 years after the discovery of the adrenocorticotropic hormone receptor (ACTHR) by Mountjoy and colleagues. In subsequent years, following the discovery of other types of mammalian melanocortin receptors (MCRs), ACTHR also became known as melanocortin type 2 receptor (MC2R). At present, five types of MCRs have been reported, all of which share significant sequence similarity at the amino acid level, and all of which specifically bind melanocortins (MCs)—a group of biologically active peptides generated by proteolysis of the proopiomelanocortin precursor. All MCs share an identical –H–F–R–W– pharmacophore sequence. α-Melanocyte-stimulating hormone (α-MSH) and adrenocorticotropic hormone (ACTH) are the most extensively studied MCs and are derived from the same region. Essentially, α-MSH is formed from the first 13 amino acid residues of ACTH. ACTHR is unique among MCRs because it binds one sole ligand—ACTH, which makes it a very attractive research object for molecular pharmacologists. However, much research has failed, and functional studies of this receptor are lagging behind other MCRs. The reason for these difficulties has already been outlined by Mountjoy and colleagues in their publication on ACTHR coding sequence discovery where the Cloudman S91 melanoma cell line was used for receptor expression because it was a “more sensitive assay system.” Subsequent work showed that ACTHR could be successfully expressed only in endogenous MCR-expressing cell lines, since in other cell lines it is retained within the endoplasmic reticulum. The resolution of this methodological problem came in 2005 with the discovery of melanocortin receptor accessory protein, which is required for the formation of functionally active ACTHR. The decade that followed this discovery was filled with exciting research that provided insight into the molecular mechanisms underlying the action of ACTHR. The purpose of this review is to summarize the advances in this fascinating research field. Frontiers Media S.A. 2017-02-06 /pmc/articles/PMC5292628/ /pubmed/28220105 http://dx.doi.org/10.3389/fendo.2017.00013 Text en Copyright © 2017 Fridmanis, Roga and Klovins. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Fridmanis, Davids Roga, Ance Klovins, Janis ACTH Receptor (MC2R) Specificity: What Do We Know About Underlying Molecular Mechanisms? |
title | ACTH Receptor (MC2R) Specificity: What Do We Know About Underlying Molecular Mechanisms? |
title_full | ACTH Receptor (MC2R) Specificity: What Do We Know About Underlying Molecular Mechanisms? |
title_fullStr | ACTH Receptor (MC2R) Specificity: What Do We Know About Underlying Molecular Mechanisms? |
title_full_unstemmed | ACTH Receptor (MC2R) Specificity: What Do We Know About Underlying Molecular Mechanisms? |
title_short | ACTH Receptor (MC2R) Specificity: What Do We Know About Underlying Molecular Mechanisms? |
title_sort | acth receptor (mc2r) specificity: what do we know about underlying molecular mechanisms? |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292628/ https://www.ncbi.nlm.nih.gov/pubmed/28220105 http://dx.doi.org/10.3389/fendo.2017.00013 |
work_keys_str_mv | AT fridmanisdavids acthreceptormc2rspecificitywhatdoweknowaboutunderlyingmolecularmechanisms AT rogaance acthreceptormc2rspecificitywhatdoweknowaboutunderlyingmolecularmechanisms AT klovinsjanis acthreceptormc2rspecificitywhatdoweknowaboutunderlyingmolecularmechanisms |